Real-time kinetic analysis and detection of glycated hemoglobin A1c using a quartz crystal microbalance-based aptasensor
Issued Date
2023-01-01
Resource Type
ISSN
17599660
eISSN
17599679
Scopus ID
2-s2.0-85182370989
Pubmed ID
38197200
Journal Title
Analytical Methods
Rights Holder(s)
SCOPUS
Bibliographic Citation
Analytical Methods (2023)
Suggested Citation
Sriondee Y., Vijitvarasan P., Rattanachata A., Nakajima H., Oaew S., Cheunkar S. Real-time kinetic analysis and detection of glycated hemoglobin A1c using a quartz crystal microbalance-based aptasensor. Analytical Methods (2023). doi:10.1039/d3ay01842c Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/95753
Title
Real-time kinetic analysis and detection of glycated hemoglobin A1c using a quartz crystal microbalance-based aptasensor
Corresponding Author(s)
Other Contributor(s)
Abstract
Glycated hemoglobin (HbA1c) has been an important biomarker for long-term diagnosis and monitoring of diabetes mellitus. The development of a rapid, reliable, and less sophisticated device to measure HbA1c is imperative to facilitate efficient early-care diabetes management. To date, no existing aptamer-based biosensor (aptasensor) for detecting HbA1c has been developed using a quartz crystal microbalance (QCM). In this study, the aptamer specific to HbA1c as a novel biosensing receptor was covalently functionalized onto a QCM substrate via mixed self-assembled monolayers (SAMs). A portable QCM equipped with a liquid-flow module was used to investigate the biospecificity, sensitivity, and interaction dynamics of the aptamer functionalized surfaces. The real-time kinetic analysis of HbA1c binding to the surface-functionalized aptamers revealed “on” and “off” binding rates of 4.19 × 104 M−1 s−1 and 2.43 × 10−3 s−1, respectively. These kinetic parameters imply that the QCM-based aptasensor specifically recognizes HbA1c with an equilibrium dissociation constant as low as 57.99 nM. The linear detection of HbA1c spanned from 13 to 108 nM, with a limit of detection (LOD) of 26.29 nM. Moreover, the spiked plasma sample analysis offered compelling evidence that this aptasensor is a promising technique for developing a point-of-care device for diabetes mellitus.